Randomized pharmacokinetic and drug–drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects

Pharmacology Research and Perspectives

Volumn 3, Issue 5, 2015, Pages

  Das, Shampa ^a   Li, Jianguo ^a   Armstrong, Jon ^a   Learoyd, Maria ^a   Edeki, Timi ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Avibactam; ceftazidime; drug drug interaction; infectious disease; pharmacokinetics

Indexed keywords

AVIBACTAM; CEFTAZIDIME; METRONIDAZOLE;

ACCURACY; ADULT; ANGIONEUROTIC EDEMA; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL PRACTICE; CONTACT DERMATITIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; GEOMETRY; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPERSENSITIVITY; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; NORMAL HUMAN; OBSERVATIONAL STUDY; PAIN; PRIORITY JOURNAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 84977964862     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.172     Document Type: Article

References (24)

1. Berkhout J, Melchers MJ, Seyedmousavi S, Lagarde CM, Schuck V, Nichols WW, et al. (2013). Exposure response relationships of ceftazidime and avibactam in a neutropenic thigh model. 53rd Intersceince Conference on Antimicrobial Agents and Chemotherapy, 2013, Denver, CO, USA.
2. Boucher HW, Talbot GH, Benjamin Jr DK, Bradley J, Guidos RJ, Jones RN, et al. (2013). 10 x ‘20 Progress – development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 56: 1685–1694.
3. Das S, Armstrong J, Mathews D, Li J, Edeki T (2014). Randomized, placebo-controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime–avibactam or ceftaroline fosamil-avibactam. J Clin Pharmacol 54: 331–340.
4. Food and Drug Administration (2012). Guidance for industry: Drug Interaction Studies - study design, data analysis, implications for dosing, and labeling recommendations. Available at http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm292362.pdf. (accessed 12 June 2015).
5. Food and Drug Administration (2015). AVYCAZ (ceftazidime–avibactam) for injection, for intravenous use: highlights of prescribing information. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206494s000lbl.pdf. (accessed 12 June 2015).
6. ® 1 g injection SPC. Available at http://www.medicines.org.uk/emc/document.aspx?documentid=19176&docType=SPC. (accessed 12 February 2014).
7. Hirsch EB, Tam VH (2010). Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 65: 1119–1125.
8. Kanj SS, Kanafani ZA (2011). Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum ß-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc 86: 250–259.
9. Lagace-Wiens PR, Tailor F, Simner P, DeCorby M, Karlowsky JA, Walkty A, et al. (2011). Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases. Antimicrob Agents Chemother 55: 2434–2437.
10. Li J, Zhou D, Al Huniti N, Bouchillon S, Bradford P, Nichols WW, et al. (2014). Pharmacokinetic/Pharmacodynamic target attainment (PTA) and cumulative fractions of response (CFR) for ceftazidime, ceftazidime–avibactam, and meropenem against bacteria isolated from patients in Europe in 2012. 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 2014, Barcelona, Spain.
11. Livermore DM, Mushtaq S, Warner M, Zhang J, Maharjan S, Doumith M, et al. (2011). Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 55: 390–394.
12. Lucasti C, Popescu I, Ramesh MK, Lipka J, Sable C (2013). Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial. J Antimicrob Chemother 68: 1183–1192.
13. Mazuski JE, Gasink L, Armstong J, Broadhurst H, Stone G, Rank D, et al. (2015). Efficacy and safety of ceftazidime–avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection - results from a Phase III programme. 25th European Congress of Clinical Microbiology and Infectious Diseases, 2015, Copenhagen, Denmark.
14. Merdjan H, Rangaraju M, Tarral A (2015). Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies. Clin Drug Investig 35: 307–317.
15. Muller AE, Punt N, Mouton JW (2013). Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. J Antimicrob Chemother 68: 900–906.
16. Peleg AY, Hooper DC (2010). Hospital-acquired infections due to gram-negative bacteria. N Engl J Med 362: 1804–1813.
17. Sillén H, Mitchell R, Sleigh R, Mainwaring G, Catton K, Houghton R, et al. (2015). Determination of avibactam and ceftazidime in human samples by liquid chromatography and mass spectrometry. Bioanalysis 7: 1423–1434.
18. Sommers DK, Walters L, Van WM, Harding SM, Paton AM, Ayrton J (1983). Pharmacokinetics of ceftazidime in male and female volunteers. Antimicrob Agents Chemother 23: 892–896.
19. Stachyra T, Levasseur P, Pechereau MC, Girard AM, Claudon M, Miossec C, et al. (2009). In vitro activity of the beta-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J Antimicrob Chemother 64: 326–329.
20. Tarral A, Merdjan H (2015). Effect of age and sex on the pharmacokinetics and safety of avibactam in healthy volunteers. Clin Ther 37: 877–886.
21. Vazquez JA, Gonzalez Patzan LD, Stricklin D, Duttaroy DD, Kreidly Z, Lipka J, et al. (2012). Efficacy and safety of ceftazidime–avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin 28: 1921–1931.
22. Vishwanathan K, Mair S, Gupta A, Atherton J, Clarkson-Jones J, Edeki T, et al. (2014). Assessment of the mass balance recovery and metabolite profile of avibactam in humans and in vitro drug–drug interaction potential. Drug Metab Dispos 42: 932–942.
23. Welage LS, Schultz RW, Schentag JJ (1984). Pharmacokinetics of ceftazidime in patients with renal insufficiency. Antimicrob Agents Chemother 25: 201–204.
24. ® 400 mg tablets SPC. Available at http://www.medicines.org.uk/emc/medicine/21216/spc. (accessed 12 February 2014).